Recombinant LAG3 antibody (AA 500-525)
-
- Target See all LAG3 Antibodies
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
- Antibody Type
- Recombinant Antibody
-
Binding Specificity
- AA 500-525
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Monoclonal
-
Conjugate
- This LAG3 antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunoprecipitation (IP), Immunocytochemistry (ICC), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections) (IHC (fp)), Multiplex Immunofluorescence (mIF)
- Purpose
- Rabbit anti-LAG3 Recombinant Monoclonal Antibody [BLR027F]
- Immunogen
- between AA 500 and 525 (C-term)
- Clone
- BLR027F
- Isotype
- IgG
- Top Product
- Discover our top product LAG3 Primary Antibody
-
-
- Application Notes
-
IHC-IF: 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
IHC: 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.
IP: 12 μL/0.5 mg lysate
ICC: 1:100 to 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE cell sections.
WB: 17:40:00
- Restrictions
- For Research Use only
-
- Concentration
- 500 μg/mL
- Buffer
- Borate Buffered Saline (BBS) pH 8.2 with 0.1 % BSA and 0.09 % Sodium Azide
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
- Expiry Date
- 12 months
-
- Target
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
- Alternative Name
- LAG3 (LAG3 Products)
- Background
- Background: Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4 [taken from NCBI Entrez Gene (Gene ID: 3902)]
- Gene ID
- 3902
- NCBI Accession
- NP_002277
- UniProt
- P18627
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
-